Femasys Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
FEMY Nasdaq 3840 femasys.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Femasys Inc.

Femasys Regains Compliance with Nasdaq Listing Requirements - Jun 24th, 2026 7:00 am
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - May 29th, 2026 4:55 pm
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - May 13th, 2026 7:00 am
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - May 8th, 2026 2:05 pm
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete - May 5th, 2026 7:00 am
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 - Apr 22nd, 2026 7:00 am
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio - Apr 16th, 2026 7:00 am
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - Apr 1st, 2026 7:00 am
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - Mar 31st, 2026 2:05 pm
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Mar 18th, 2026 7:00 am
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment - Mar 10th, 2026 7:00 am
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 27th, 2026 3:26 pm
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Feb 26th, 2026 7:00 am
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Feb 23rd, 2026 7:00 am
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - Feb 3rd, 2026 7:15 am
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Jan 14th, 2026 7:00 am
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - Jan 13th, 2026 7:00 am
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - Dec 18th, 2025 7:15 am
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Nov 25th, 2025 7:15 am
Femasys Announces Third Quarter Financial Results for 2025 - Nov 14th, 2025 2:01 pm